Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.
John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...
Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.
Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results